Immunogenicity and safety of Sotrovimab (Vir 7831) IV as primary prophylaxis in anti-SARS-CoV-2 vaccine non responders

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2021
This article has no abstract
Epistemonikos ID: b6e11f2fe1285dab92b448c43cc911e54e3a571b
First added on: Mar 09, 2022